Leerink Partnrs Issues Positive Outlook for Arvinas Earnings

Arvinas, Inc. (NASDAQ:ARVN) – Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Arvinas in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous estimate of ($0.50). The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.07) EPS, FY2026 earnings at ($2.66) EPS and FY2027 earnings at $1.77 EPS.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same period in the previous year, the business posted ($2.53) earnings per share.

Other analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $87.00 price target on shares of Arvinas in a research note on Wednesday, December 11th. Barclays lowered their target price on Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Stifel Nicolaus dropped their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating for the company in a report on Wednesday. Guggenheim reaffirmed a “buy” rating and issued a $57.00 price target on shares of Arvinas in a research note on Wednesday. Finally, Wedbush reissued an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research note on Tuesday. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $59.58.

Arvinas Stock Performance

Shares of ARVN opened at $17.67 on Friday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The firm has a 50 day moving average price of $19.04 and a 200-day moving average price of $23.28. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -3.78 and a beta of 1.88.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARVN. Vanguard Group Inc. boosted its position in Arvinas by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 7,062,561 shares of the company’s stock valued at $135,389,000 after acquiring an additional 56,561 shares in the last quarter. FMR LLC boosted its position in shares of Arvinas by 7.6% during the third quarter. FMR LLC now owns 2,883,604 shares of the company’s stock valued at $71,023,000 after purchasing an additional 204,317 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company’s stock valued at $57,371,000 after purchasing an additional 367,343 shares in the last quarter. New Leaf Venture Partners L.L.C. grew its stake in Arvinas by 10.5% in the fourth quarter. New Leaf Venture Partners L.L.C. now owns 1,585,721 shares of the company’s stock worth $30,398,000 after purchasing an additional 151,000 shares during the period. Finally, Braidwell LP raised its holdings in Arvinas by 148.3% in the third quarter. Braidwell LP now owns 1,284,472 shares of the company’s stock worth $31,637,000 after purchasing an additional 767,242 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.